Joseph Todisco - Amneal Pharmaceuticals, President
| AMRX Stock | USD 7.92 0.18 2.22% |
President
Mr. Joseph Todisco is a Senior Vice President, Specialty Commercial of the Company. Joe has leadership responsibility for Specialty and International, as well as continued responsibility for the AmnealImpax integration process. Joe joined Amneal six years ago as the head of Corporationrationrate Development and was an integral part of the management team that executed the AmnealImpax business combination, as well as multiple other business development, licensing and MA transactions. In addition to his role in Corporationrationrate Development, Joe held management oversight responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxys North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer Co. and also worked in financial services for Marsh McLennan Companies. Joe holds a bachelors degree in Economics from Georgetown University in Washington D.C. and an M.B.A. from Fordham Graduate School of Business in New York. since 2020.
| Age | 45 |
| Tenure | 4 years |
| Professional Marks | MBA |
| Address | 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807 |
| Phone | 908 947 3120 |
| Web | https://amneal.com |
Amneal Pharmaceuticals, Management Efficiency
The company has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Janssen | Dynavax Technologies | 70 | |
| Kurt Knab | Evolus Inc | N/A | |
| Marcela Pagano | Procaps Group SA | 57 | |
| John Condon | Intracellular Th | N/A | |
| Lisa Escudero | Phibro Animal Health | 62 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Mark Neumann | Intracellular Th | 61 | |
| Michael Landine | Alkermes Plc | 70 | |
| Luis Aragon | Procaps Group SA | 60 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Samson Li | Phibro Animal Health | 52 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Crystal Muilenburg | Evolus Inc | 44 | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| Parker Javid | Lifecore Biomedical | 55 | |
| John Bardi | Intracellular Th | N/A | |
| David Gaffin | Alkermes Plc | 52 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | 0.0594 |
Amneal Pharmaceuticals, Leadership Team
Elected by the shareholders, the Amneal Pharmaceuticals,'s board of directors comprises two types of representatives: Amneal Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amneal. The board's role is to monitor Amneal Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Amneal Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amneal Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanjay Jain, President Operations | ||
| Anastasios Konidaris, Chief Financial Officer, Executive Vice President | ||
| John Kiely, Independent Director | ||
| Gautam Patel, Director | ||
| Pranav Mehta, Senior Management | ||
| Nikita Shah, Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer | ||
| Paul Meister, Independent Chairman of the Board | ||
| Jason Esq, Chief VP | ||
| Andrew Boyer, Executive Vice President, Chief Commercial Officer - Generics | ||
| Ted Nark, Independent Director | ||
| Jeffrey George, Independent Director | ||
| Shlomo Yanai, Independent Director | ||
| Nikunj Patel, Head Ltd | ||
| Gregory Sgammato, Senior Development | ||
| Chintu Patel, Co-Chief Executive Officer, Co-Founder, Director | ||
| Stephen Manzano, Senior Vice President, General Counsel and Corporate Secretary | ||
| Sanjiv Patel, VP Operations | ||
| Emily Alva, Independent Director | ||
| Anthony DiMeo, Director Relations | ||
| Joseph Greer, Senior Vice President - Global Quality Management | ||
| Jason Daly, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| Apurva Saraf, Senior Vice President - Corporate Development | ||
| Chintu RPh, CoCEO CoFounder | ||
| RPh RPh, CoCEO CoFounder | ||
| J Buchi, Independent Director | ||
| Chirag Patel, President, Co-Chief Executive Officer, Co-Founder, Director | ||
| Joseph Todisco, Executive Vice President, Chief Commercial Officer - Specialty |
Amneal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amneal Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | 0.0594 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 5.08 B | ||||
| Shares Outstanding | 309.84 M | ||||
| Shares Owned By Insiders | 52.19 % | ||||
| Shares Owned By Institutions | 46.48 % | ||||
| Number Of Shares Shorted | 4.67 M | ||||
| Price To Earning | 230.50 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.